In order to investigate whether NOX4 is involved in the targeted therapy resistance of ovarian cancer, we tested whether NOX4 knockdown affected the sensitivity of ovarian cancer to trastuzumab (HER2 inhibitor) treatment. This evidence concerns the gene ERBB2 and ovarian carcinoma.